Repare Therapeutics Stock Performance
| RPTX Stock | USD 2.81 0.16 5.39% |
The company holds a Beta of 1.0, which implies a somewhat significant risk relative to the market. Repare Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Repare Therapeutics is expected to follow. At this point, Repare Therapeutics has a negative expected return of -0.0862%. Please make sure to check Repare Therapeutics' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Repare Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Repare Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Repare Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (5.39) | Five Day Return (9.65) | Year To Date Return (61.45) | Ten Year Return (90.88) | All Time Return (90.88) |
1 | Repare Therapeutics stock hits 52-week low at 2.76 By Investing.com - Investing.com UK | 09/04/2024 |
2 | Repare Therapeutics to Present Data from Phase 12 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-o... | 09/13/2024 |
3 | Repare Therapeutics Inc. institutional owners may be pleased with recent gains after 68 percent loss over the past year | 09/16/2024 |
4 | Repare Therapeutics Inc. is definitely on the radar of institutional investors who own 36 percent of the company | 09/27/2024 |
5 | Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Pol ATPase Inhibitor | 10/14/2024 |
6 | Disposition of 825 shares by Steve Forte of Repare Therapeutics at 4.62 subject to Rule 16b-3 | 10/18/2024 |
7 | Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial | 10/23/2024 |
8 | Acquisition by Rhoads Ann D of 27200 shares of Repare Therapeutics at 3.8 subject to Rule 16b-3 | 11/01/2024 |
9 | Repare Therapeutics GAAP EPS of -0.81 | 11/07/2024 |
10 | Repare Therapeutics collaborates with U.S. National Cancer Institute | 11/12/2024 |
11 | Analysts Revenue Estimates For Repare Therapeutics Inc. Are Surging Higher | 11/13/2024 |
| Begin Period Cash Flow | 159.5 M |
Repare |
Repare Therapeutics Relative Risk vs. Return Landscape
If you would invest 316.00 in Repare Therapeutics on August 26, 2024 and sell it today you would lose (35.00) from holding Repare Therapeutics or give up 11.08% of portfolio value over 90 days. Repare Therapeutics is currently does not generate positive expected returns and assumes 4.4389% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Repare, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Repare Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Repare Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Repare Therapeutics, and traders can use it to determine the average amount a Repare Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0194
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RPTX |
Estimated Market Risk
| 4.44 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Repare Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Repare Therapeutics by adding Repare Therapeutics to a well-diversified portfolio.
Repare Therapeutics Fundamentals Growth
Repare Stock prices reflect investors' perceptions of the future prospects and financial health of Repare Therapeutics, and Repare Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repare Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.26) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | (57.41 M) | ||||
| Shares Outstanding | 42.51 M | ||||
| Price To Book | 0.68 X | ||||
| Price To Sales | 1.80 X | ||||
| Revenue | 51.13 M | ||||
| Gross Profit | 15.11 M | ||||
| EBITDA | (114.27 M) | ||||
| Net Income | (93.8 M) | ||||
| Cash And Equivalents | 282.09 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 3.41 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 7.35 X | ||||
| Book Value Per Share | 4.12 X | ||||
| Cash Flow From Operations | (127.16 M) | ||||
| Earnings Per Share | (1.99) X | ||||
| Market Capitalization | 119.46 M | ||||
| Total Asset | 253.9 M | ||||
| Retained Earnings | (333.11 M) | ||||
| Working Capital | 204.61 M | ||||
About Repare Therapeutics Performance
Evaluating Repare Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Repare Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Repare Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (220.23) | (231.24) | |
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.44) | (0.42) |
Things to note about Repare Therapeutics performance evaluation
Checking the ongoing alerts about Repare Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repare Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Repare Therapeutics generated a negative expected return over the last 90 days | |
| Repare Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 51.13 M. Net Loss for the year was (93.8 M) with profit before overhead, payroll, taxes, and interest of 15.11 M. | |
| Repare Therapeutics currently holds about 282.09 M in cash with (127.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Repare Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Analysts Revenue Estimates For Repare Therapeutics Inc. Are Surging Higher |
- Analyzing Repare Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repare Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Repare Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repare Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repare Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repare Therapeutics' stock. These opinions can provide insight into Repare Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.